NDC80 status pinpoints mitotic kinase inhibitors as emerging therapeutic options in clear cell renal cell carcinoma

∼30% of clear cell renal cell carcinoma (ccRCC) patients present with metastatic disease at the time of diagnosis, causing a dire 5-year survival rate of 13%. Although anti-PD-1 immunotherapy has improved survival, a strong need remains for new therapeutic options. Using integrated network analysis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Cheng, Lin, Weiming, Zhao, Kemeng, Tian, Guiyou, Kong, Xiangquan, Luo, Guangcheng, Wolf, Dieter A., Cheng, Yabin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130926/
https://www.ncbi.nlm.nih.gov/pubmed/37123230
http://dx.doi.org/10.1016/j.isci.2023.106531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130926/
https://www.ncbi.nlm.nih.gov/pubmed/37123230
http://dx.doi.org/10.1016/j.isci.2023.106531

Ejemplares similares